secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115675
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Q3 2022: IMCIVREE revenue $4.3M; net loss $40.9M; cash $347.8M
---------------------------------------------------------------------

- Product revenue $4.3M vs $1.0M YoY; net loss $40.9M ($0.79/share) vs $35.1M ($0.70).
- More than 120 IMCIVREE prescriptions written for BBS since FDA approval; 40+ approved for reimbursement.
- FDA Breakthrough Therapy Designation for setmelanotide in hypothalamic obesity; Phase 3 trial to start early 2023.
- Completed public offering netting $131.2M; extended cash runway into 2025.
- Appointed Dana Washburn as SVP Clinical Development; EC expanded approval for IMCIVREE in BBS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/0001104659-22-115675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/tm2229796d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer